nference has announced a strategic partnership with Parabilis Medicines to advance clinical development of Parabilis' lead colorectal cancer program, FOG-001. Through nference’s nSights platform, Parabilis researchers will gain access to extensive multimodal clinical data from millions of cancer patients, supporting data contextualization, target identification, and biomarker discovery. This collaboration aims to enhance patient targeting and real-world outcome insights, boosting the potential of FOG-001, a beta-catenin inhibitor currently in Phase 1/2 trials.
Dr. AJ Venkatakrishnan of nference highlighted the commitment to improving cancer treatment through AI-driven insights, while Parabilis’ Dr. Brandon Allgood emphasized the transformative impact of combining real-world data with advanced AI to accelerate precision medicine.
“At nference, we are committed to advancing cancer care by harnessing AI and real-world patient journeys to unlock valuable insights that can drive better treatment outcomes,” commented Dr. AJ Venkatakrishnan, SVP of Strategic AI Partnerships at nference.
Dr. Brandon Allgood, Chief Data Science Officer at Parabilis stated “We are excited about this collaboration with nference,” “The nSights platform will enable us to tap into a large depth of real-world, multimodal clinical data, helping us identify optimal patient populations and improve the targeting of our programs. By combining advanced AI, robust computational methods, and a continuous learning system built on our growing data repository, we are creating a transformative platform that not only accelerates drug discovery and development but also increases the precision and success of our therapeutic programs.”
Click here to read the original news story.